ANI PHARMACEUTICALS INC (ANIP) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ANI PHARMACEUTICALS INC Do?
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota. ANI PHARMACEUTICALS INC (ANIP) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Nikhil Lalwani and employs approximately 600 people, headquartered in Baudette, Minnesota. With a market capitalization of $1.7B, ANIP is one of the notable companies in the Healthcare sector.
ANI PHARMACEUTICALS INC (ANIP) Stock Rating — Reduce (April 2026)
As of April 2026, ANI PHARMACEUTICALS INC receives a Reduce rating with a composite score of 42.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ANIP ranks #2,670 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ANI PHARMACEUTICALS INC ranks #357 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ANIP Stock Price and 52-Week Range
ANI PHARMACEUTICALS INC (ANIP) currently trades at $80.00. The stock lost $0.14 (0.2%) in the most recent trading session. The 52-week high for ANIP is $99.50, which means the stock is currently trading -19.6% from its annual peak. The 52-week low is $56.71, putting the stock 41.1% above its annual trough. Recent trading volume was 5K shares, suggesting relatively thin trading activity.
Is ANIP Overvalued or Undervalued? — Valuation Analysis
ANI PHARMACEUTICALS INC (ANIP) carries a value factor score of 68/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 66.76x, compared to the Healthcare sector average of 23.63x — a premium of 183%. The price-to-book ratio stands at 3.29x, versus the sector average of 2.75x. The price-to-sales ratio is 2.27x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ANIP trades at 12.69x EV/EBITDA, versus 6.34x for the sector.
Overall, ANIP's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
ANI PHARMACEUTICALS INC Profitability — ROE, Margins, and Quality Score
ANI PHARMACEUTICALS INC (ANIP) earns a quality factor score of 41/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 4.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 1.8% versus the sector average of -33.1%.
On a margin basis, ANI PHARMACEUTICALS INC reports gross margins of 59.0%, compared to 71.5% for the sector. The operating margin is 5.5% (sector: -66.1%). Net profit margin stands at 1.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 65.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
ANIP Debt, Balance Sheet, and Financial Health
ANI PHARMACEUTICALS INC has a debt-to-equity ratio of 166.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.71x, indicating strong short-term liquidity. Total debt on the balance sheet is $620M. Cash and equivalents stand at $263M.
ANIP has a beta of 0.51, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ANI PHARMACEUTICALS INC is 72/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
ANI PHARMACEUTICALS INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, ANI PHARMACEUTICALS INC reported revenue of $785M and earnings per share (EPS) of $3.50. Net income for the quarter was $27M. Gross margin was 59.0%. Operating income came in at $56M.
In FY 2025, ANI PHARMACEUTICALS INC reported revenue of $883M and earnings per share (EPS) of $3.50. Net income for the quarter was $78M. Revenue grew 43.8% year-over-year compared to FY 2024. Operating income came in at $111M.
In Q3 2025, ANI PHARMACEUTICALS INC reported revenue of $228M and earnings per share (EPS) of $1.19. Net income for the quarter was $27M. Revenue grew 53.6% year-over-year compared to Q3 2024. Operating income came in at $36M.
In Q2 2025, ANI PHARMACEUTICALS INC reported revenue of $211M and earnings per share (EPS) of $0.37. Net income for the quarter was $9M. Revenue grew 53.1% year-over-year compared to Q2 2024. Operating income came in at $14M.
Over the past 8 quarters, ANI PHARMACEUTICALS INC has demonstrated a growth trajectory, with revenue expanding from $138M to $785M. Investors analyzing ANIP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ANIP Dividend Yield and Income Analysis
ANI PHARMACEUTICALS INC (ANIP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ANIP Momentum and Technical Analysis Profile
ANI PHARMACEUTICALS INC (ANIP) has a momentum factor score of 40/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ANIP vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, ANI PHARMACEUTICALS INC (ANIP) ranks #357 out of 838 stocks based on the Blank Capital composite score. This places ANIP in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ANIP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ANIP vs S&P 500 (SPY) comparison to assess how ANI PHARMACEUTICALS INC stacks up against the broader market across all factor dimensions.
ANIP Next Earnings Date
No upcoming earnings date has been announced for ANI PHARMACEUTICALS INC (ANIP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ANIP? — Investment Thesis Summary
The quantitative profile for ANI PHARMACEUTICALS INC suggests caution. The value score of 68/100 suggests attractive pricing relative to fundamentals. Low volatility (stability score 72/100) reduces downside risk.
In summary, ANI PHARMACEUTICALS INC (ANIP) earns a Reduce rating with a composite score of 42.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ANIP stock.
Related Resources for ANIP Investors
Explore more research and tools: ANIP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ANIP head-to-head with peers: ANIP vs AZN, ANIP vs SLGL, ANIP vs VMD.